3rd Biennial Miami Precision Medicine

Saturday, April 11, 2026, 6:30 AM - Sunday, April 12, 2026, 6:30 PM, Ritz-Carlton Fort Lauderdale, Fort Lauderdale , FL


AMA PRA Category 1 Credits™ (11.75 hours), Non-Physician Attendance (11.75 hours)

The 3rd Biennial Miami Precision Medicine (MPM) 2026 conference (MPM) is the first international conference of its kind presented by the Sylvester Comprehensive Cancer Center, South Florida‘s Only NCI-Designated Cancer Center. It brings together diverse experts in the field to share their knowledge and approaches in moving the precision medicine field towards routine practice. Precision Oncology- treating the right patient with the right treatment at the right time- has made substantial progress in developing novel and effective treatments that target specific molecular alterations in an increasing number of cancer types. This year's conference will have 2 sessions: Provider and Patient Provider Session - Advancing Precision Medicine: This session will focus on the integration of precision medicine into routine cancer care. Hear from national and international leaders about emerging innovations, clinical applications and the future of personalized oncology. Topics will include germline and genomic testing, multi-omics, molecular pathways, novel treatment and artificial intelligence. Patient Session - Empowering Survivors: Living Longer, Living Better: Designed for patients and advocates, this session will highlight role of germline and genomic testing, principles of precision oncology and survivorship, role of clinical trials and more. Topics will include cancer prevention and treatment, lifestyle medicine and survivorship care. The conference will examine the treatment landscape for various cancer types based on published and emerging data on: • Immuno-Oncology • Oncology Biomarkers • Molecular Alterations • Hematology • Pediatric Oncology • GI Cancers • Neuro Oncology • Breast Cancer • Genitourinary (Prostate, Bladder and Kidney) Cancers • Gynecologic Oncology • Sarcoma • Leukemia • Lung Cancer The conference will also illustrate the role of Artificial Intelligence (AI) in identifying patterns and innovative strategies for specific cancers and individual patient populations. An interdisciplinary molecular tumor board case discussion will emphasize the role of germline and genomic alterations in selecting targeted treatments as well as present relevant precision medicine clinical trials.

1. Expedite adoption of germline and genomic testing in clinical practice
2. Interpret next generation sequencing (NGS) results
3. Interpret results of a liquid biopsy (ctDNA)
4. Explain the role of multi-omics in precision oncology
5. Summarize role of biomarkers in selection of targeted therapies and immunotherapies in different cancer types
6. Recognize the emerging role of Artificial Intelligence in precision medicine
7. Describe common molecular alterations and the role of molecular diagnostic tests in different cancer types
8. Summarize recent and emerging data from key studies in clinical and translational cancer research
9. Implement strategies designed to improve the quality of cancer care, address barriers to optimal care and enhance the patient experience
10. Identify the role of lifestyle intervention in the precision medicine care model
11. Identify the role of scentific advances in the field of cancer biology and tumor pathogenesis
12. Develop collaborations that will lead to improved clinical trial portfolio and clinical trial participation
13. Interact with patients and patient advocacy groups to promote access to molecularly-driven therapies and available clinical trials
14. Facilitate patient-oncology experts' interaction and understanding of survivorship challenges in the era of precision medicine

 

The University of Miami Leonard M. Miller School of Medicine designates this Live Activity for a maximum of 11.75 of AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Registration and Cancellation Policy

Cancellations received in writing no less than 30 days before the course will be refunded, less a 20% administrative fee. No refunds will be made on cancellations received after that date. Please send cancellation requests to Towers Marketing Group, [email protected].

University of Miami Healthcare System reserves the right to cancel or postpone this program if necessary; in the event of cancellation, course fees will be fully refunded. We are not responsible for other costs incurred such as non-refundable airline tickets or hotel penalties.

Services for the Disabled

University of Miami Healthcare System is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008. If you have needs that require special accommodations, including dietary concerns, please contact the CME Conference Coordinator.

Accessibility Statement
 
University of Miami Healthcare System is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require special accommodations, including dietary concerns, please contact the CME Conference Coordinator.

Mitigation of Relevant Financial Relationships

The University of Miami adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.